Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Idexx Laboratories ( (IDXX) ) has provided an announcement.
On November 12, 2025, IDEXX Laboratories, Inc. and its subsidiaries entered into Amendment No. 2 to their fourth amended and restated credit agreement, involving a $1.0 billion unsecured revolving credit facility and a $250 million term loan. This amendment extends the maturity dates, adds IDEXX Holdings II GmbH as a borrower, and introduces various financial and operational adjustments, impacting the company’s financial flexibility and operational capacity.
The most recent analyst rating on (IDXX) stock is a Hold with a $775.00 price target. To see the full list of analyst forecasts on Idexx Laboratories stock, see the IDXX Stock Forecast page.
Spark’s Take on IDXX Stock
According to Spark, TipRanks’ AI Analyst, IDXX is a Outperform.
Idexx Laboratories demonstrates strong financial performance and positive earnings call sentiment, driving the overall score. The technical analysis indicates a strong upward trend, though the high valuation and overbought RSI suggest caution. The company’s strategic focus on innovation and international growth supports its robust outlook.
To see Spark’s full report on IDXX stock, click here.
More about Idexx Laboratories
IDEXX Laboratories, Inc. operates in the veterinary, livestock, poultry, water testing, and dairy markets, providing diagnostic and information technology-based products and services.
Average Trading Volume: 455,584
Technical Sentiment Signal: Buy
Current Market Cap: $56.98B
For an in-depth examination of IDXX stock, go to TipRanks’ Overview page.